^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Positive Breast Cancer
    Drug Class:Aromatase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2 Positive Breast Cancer: Invasive Breast Cancer…SYSTEMIC THERAPY FOR ER - AND/OR PR - POSITIVE RECURRENT OR STAGE IV (M1) DISEASE…HER2-Positive and Postmenopausal Receiving Ovarian Ablation or Suppression…Aromatase inhibhitor+/-trastuzumab
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-BC 2023
    Title:

    141P - Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis (ID 354)

    Published date:
    05/07/2023
    Excerpt:
    Our findings provide evidence for the efficacy and safety of concurrent neoadjuvant endocrine therapy (AIs) with chemotherapy as an available option to achieve a higher clinical response rate for HR+HER2- breast cancer patients compared with chemotherapy alone with low toxicity.
    Secondary therapy:
    Chemotherapy